DHA Supplementation in Patients With STGD3

Completed · Not applicable

Conditions studied: Dominantly Inherited Stargardt's Disease (STGD3)

In brief

We have found that biomarkers of long-term elevated dietary intake of omega-3 fatty acids such as DHA and EPA are inversely associated with severity of disease phenotype in STGD3 patients. Therefore, the purpose of this study is to follow STGD3 patients as they supplement their diets with DHA/EPA.

Key facts

Study ID

NCT00420602

Run by

University of Utah

People needed

11

Starts

2007-09-21

Expected to finish

2017-12-27

Last updated by the study team

2018-05-09

Who can join

Age: 18 and older, up to 105. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All Moran Eye Center patients with STGD3

You may not qualify if…

• All others

Where it is running

• Moran Eye Center, University of Utah — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.